Hit and lead criteria in drug discovery for infectious diseases of the developing world

被引:466
作者
Katsuno, Kei [1 ]
Burrows, Jeremy N. [2 ]
Duncan, Ken [3 ]
van Huijsduijnen, Rob Hooft [2 ]
Kaneko, Takushi [4 ]
Kita, Kiyoshi [5 ]
Mowbray, Charles E. [6 ]
Schmatz, Dennis [2 ]
Warner, Peter [3 ]
Slingsby, B. T. [1 ]
机构
[1] Global Hlth Innovat Technol GHIT Fund, Minato Ku, Tokyo 1060032, Japan
[2] Med Malaria Venture, CH-1215 Geneva 15, Switzerland
[3] Bill & Melinda Gates Fdn, Seattle, WA 98102 USA
[4] Global Alliance TB Drug Dev, TB Alliance, New York, NY 10005 USA
[5] Univ Tokyo, Bunkyo Ku, Tokyo 1130033, Japan
[6] Drugs Neglected Dis Initiat, CH-1202 Geneva, Switzerland
关键词
PLASMODIUM-FALCIPARUM; ARTEMISININ RESISTANCE; TUBERCULOSIS; MALARIA; MODEL; ASSAY; CHALLENGES; MECHANISM; IDENTIFY; INHIBITORS;
D O I
10.1038/nrd4683
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Reducing the burden of infectious diseases that affect people in the developing world requires sustained collaborative drug discovery efforts. The quality of the chemical starting points for such projects is a key factor in improving the likelihood of clinical success, and so it is important to set clear go/no-go criteria for the progression of hit and lead compounds. With this in mind, the Japanese Global Health Innovative Technology (GHIT) Fund convened with experts from the Medicines for Malaria Venture, the Drugs for Neglected Diseases initiative and the TB Alliance, together with representatives from the Bill & Melinda Gates Foundation, to set disease-specific criteria for hits and leads for malaria, tuberculosis, visceral leishnnaniasis and Chagas disease. Here, we present the agreed criteria and discuss the underlying rationale.
引用
收藏
页码:751 / 758
页数:8
相关论文
共 82 条
[1]   A Murine Model of falciparum-Malaria by In Vivo Selection of Competent Strains in Non-Myelodepleted Mice Engrafted with Human Erythrocytes [J].
Angulo-Barturen, Inigo ;
Belen Jimenez-Diaz, Maria ;
Mulet, Teresa ;
Rullas, Joaquin ;
Herreros, Esperanza ;
Ferrer, Santiago ;
Jimenez, Elena ;
Mendoza, Alfonso ;
Regadera, Javier ;
Rosenthal, Philip J. ;
Bathurst, Ian ;
Pompliano, David L. ;
Gomez de las Heras, Federico ;
Gargallo-Viola, Domingo .
PLOS ONE, 2008, 3 (05)
[2]   Malaria and Artemisinin Derivatives: An Updated Review [J].
Ansari, Muhammad Tayyab ;
Saify, Zafar Saeed ;
Sultana, Nighat ;
Ahmad, Imran ;
Saeed-Ul-Hassan, Syed ;
Tariq, Imran ;
Khanum, Munawer .
MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2013, 13 (13) :1879-1902
[3]   A molecular marker of artemisinin-resistant Plasmodium falciparum malaria [J].
Ariey, Frederic ;
Witkowski, Benoit ;
Amaratunga, Chanaki ;
Beghain, Johann ;
Langlois, Anne-Claire ;
Khim, Nimol ;
Kim, Saorin ;
Duru, Valentine ;
Bouchier, Christiane ;
Ma, Laurence ;
Lim, Pharath ;
Leang, Rithea ;
Duong, Socheat ;
Sreng, Sokunthea ;
Suon, Seila ;
Chuor, Char Meng ;
Bout, Denis Mey ;
Menard, Sandie ;
Rogers, William O. ;
Genton, Blaise ;
Fandeur, Thierry ;
Miotto, Olivo ;
Ringwald, Pascal ;
Le Bras, Jacques ;
Berry, Antoine ;
Barale, Jean-Christophe ;
Fairhurst, Rick M. ;
Benoit-Vical, Franoise ;
Mercereau-Puijalon, Odile ;
Menard, Didier .
NATURE, 2014, 505 (7481) :50-+
[4]   Spread of Artemisinin Resistance in Plasmodium falciparum Malaria [J].
Ashley, E. A. ;
Dhorda, M. ;
Fairhurst, R. M. ;
Amaratunga, C. ;
Lim, P. ;
Suon, S. ;
Sreng, S. ;
Anderson, J. M. ;
Mao, S. ;
Sam, B. ;
Sopha, C. ;
Chuor, C. M. ;
Nguon, C. ;
Sovannaroth, S. ;
Pukrittayakamee, S. ;
Jittamala, P. ;
Chotivanich, K. ;
Chutasmit, K. ;
Suchatsoonthorn, C. ;
Runcharoen, R. ;
Hien, T. T. ;
Thuy-Nhien, N. T. ;
Thanh, N. V. ;
Phu, N. H. ;
Htut, Y. ;
Han, K-T. ;
Aye, K. H. ;
Mokuolu, O. A. ;
Olaosebikan, R. R. ;
Folaranmi, O. O. ;
Mayxay, M. ;
Khanthavong, M. ;
Hongvanthong, B. ;
Newton, P. N. ;
Onyamboko, M. A. ;
Fanello, C. I. ;
Tshefu, A. K. ;
Mishra, N. ;
Valecha, N. ;
Phyo, A. P. ;
Nosten, F. ;
Yi, P. ;
Tripura, R. ;
Borrmann, S. ;
Bashraheil, M. ;
Peshu, J. ;
Faiz, M. A. ;
Ghose, A. ;
Hossain, M. A. ;
Samad, R. .
NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (05) :411-423
[5]   Chemical con artists foil drug discovery [J].
Baell, Jonathan ;
Walters, Michael A. .
NATURE, 2014, 513 (7519) :481-483
[6]   New Substructure Filters for Removal of Pan Assay Interference Compounds (PAINS) from Screening Libraries and for Their Exclusion in Bioassays [J].
Baell, Jonathan B. ;
Holloway, Georgina A. .
JOURNAL OF MEDICINAL CHEMISTRY, 2010, 53 (07) :2719-2740
[7]  
Borel JF, 2002, WIEN KLIN WOCHENSCHR, V114, P433
[8]   A major transition in malaria treatment: The adoption and deployment of artemisinin-based combination therapies [J].
Bosman, Andrea ;
Mendis, Kamini N. .
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2007, 77 (06) :193-197
[9]   R406, an orally available spleen tyrosine kinase inhibitor blocks Fc receptor signaling and reduces immune complex-mediated inflammation [J].
Braselmann, Sylvia ;
Taylor, Vanessa ;
Zhao, Haoran ;
Wang, Su ;
Sylvain, Catherine ;
Baluom, Muhammad ;
Qu, Kunbin ;
Herlaar, Ellen ;
Lau, Angela ;
Young, Chi ;
Wong, Brian R. ;
Lovell, Scott ;
Sun, Thomas ;
Park, Gary ;
Argade, Ankush ;
Jurcevic, Stipo ;
Pine, Polly ;
Singh, Rajinder ;
Grossbard, Elliott B. ;
Payan, Donald G. ;
Masuda, Esteban S. .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2006, 319 (03) :998-1008
[10]   MICROBIOLOGY Malaria runs rings round artemisinin [J].
Burrows, Jeremy .
NATURE, 2015, 520 (7549) :628-630